Acute ST Elevation Myocardial Infarction Clinical Trial
Official title:
Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Large Myocardial Infarctions
The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.
REVEAL is a randomized, double-blinded, placebo-controlled, parallel phase II clinical study that will evaluate the effects of erythropoietin administration on infarct size, left ventricular remodeling and circulating endothelial progenitor cells in patients with large myocardial infarctions (MI). The study will be conducted in two phases: a dose-escalation safety phase and a single dose efficacy phase. Eligible patients who present to the hospital with an acute ST-elevation MI and who agree to participate in this study will be randomly assigned to receive a single infusion of study medication consisting either of erythropoietin or placebo. The size of the infarction and the dimensions of the heart will be assessed by cardiac magnetic resonance imaging (MRI) within 2-6 days of the infusion of the study medication, and again approximately 3 months later. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02835534 -
The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI
|
Phase 4 | |
| Completed |
NCT01388504 -
Nitrites in Acute Myocardial Infarction
|
Phase 2/Phase 3 | |
| Completed |
NCT01878487 -
Assessment of Lumen Expansion After Thrombus Extraction in Primary Percutaneous Coronary Intervention
|
N/A | |
| Recruiting |
NCT00284323 -
Salvage: Postconditioning With Adenosine for STEMI
|
Phase 2 | |
| Completed |
NCT01519518 -
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
|
Phase 4 |